Sporadic vs Familial Parkinson's Disease: Comprehensive Comparison
Pathway / Mechanism Diagram
Mermaid diagram (expand to render)
Overview
Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease, affecting approximately 1-2% of the population over 65 years and rising to 3-5% in those over 85. The disease is characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta and the presence of Lewy bodies—intraneuronal inclusions primarily composed of aggregated alpha-synuclein (α-syn).
PD exists on a clinical and genetic spectrum, with both familial (genetic) forms accounting for approximately 10-15% of cases and sporadic (idiopathic) forms representing the majority (85-90%) [@kalia2015]. While both forms share the core pathological features of dopaminergic neuron loss and Lewy body pathology, they differ in their genetic architecture, age of onset, clinical phenotype, rate of progression, and therapeutic responses.
Familial PD is caused by highly penetrant mutations in specific genes that follow Mendelian inheritance patterns. These mutations are typically either autosomal dominant (LRRK2, SNCA, VPS35) or autosomal recessive (PARK2/PARKIN, PINK1, PARK7/DJ-1, ATP13A2) [@blanka2015].
Sporadic PD arises from a complex interplay of multiple genetic risk variants (polygenic) combined with environmental factors. The largest genetic risk factor is common variants in the [GBA](/genes/gba) gene, with numerous other loci identified through genome-wide association studies (GWAS) contributing to overall risk [@sidransky2009].
Genetic Architecture Comparison
Overview Table
| Feature | Familial PD | Sporadic PD |
|---------|-------------|-------------|
| Proportion of all PD | 10-15% | 85-90% |
| Primary Genes | LRRK2, SNCA, VPS35 (AD); PARK2, PINK1, PARK7 (AR) | GBA, ~90+ risk loci |
| Inheritance Pattern | Autosomal dominant/recessive | Polygenic, complex |
| Onset Age | 20-65 years (depending on gene) | >60 years (mean ~62) |
| Penetrance | Variable (30-100%) | Very low (~5-10% lifetime risk) |
| Family History | Clear (multiple affected generations) | Often absent |
| Causative vs Risk | Causative (pathogenic) | Risk alleles (modify susceptibility) |
| Mutation Type | Highly penetrant missense/nonsense | Common variants (mostly non-coding) |
Familial PD Genes
LRRK2 (Leucine-Rich Repeat Kinase 2)
Gene Location: Chromosome 12q12
Inheritance: Autosomal dominant
Prevalence:
- Accounts for 5-10% of familial PD
- 1-2% of sporadic PD (European populations)
- G2019S is the most common mutation (~5% familial, ~1% sporadic)
- Higher prevalence in certain ethnic groups (up to 40% in some Arab populations)
- Founder effects in Basque, Northern Spanish, and Caribbean populations
Pathogenic Mutations:| Mutation | Location | Effect | Prevalence | Notes |
|---------|----------|--------|------------|-------|
| G2019S | Kinase domain | Increased kinase activity | 5% familial, 1% sporadic | Most common |
| R1441C/G/H | ROC domain | Altered GTPase activity | Rare | Variable penetrance |
| I2020T | COR domain | Variable | Rare | First identified in Japanese families |
| Y1699C | WD40 domain | Unknown | Rare | Less common |
| G2385R | Kinase domain | Asian risk variant | 8-10% (Asian) | Not fully penetrant |
Mechanism:
- LRRK2 is a large protein (2527 amino acids) with multiple functional domains
- Pathogenic mutations generally increase kinase activity
- LRRK2 is expressed in dopaminergic neurons and immune cells
- Functions include: cytoskeletal dynamics, synaptic vesicle trafficking, autophagy, inflammation
Clinical Phenotype:
- Typically classic PD phenotype (tremor, bradykinesia, rigidity)
- Mean age of onset: 55-60 years (similar to sporadic)
- Often good levodopa response
- May have slower progression than other genetic forms
- Some carriers may be asymptomatic into elderly age
Pathology:
- Typical Lewy body pathology
- Variable alpha-synuclein deposition
- May have less prominent Lewy bodies in some cases
Key References: [@zimpprich2011][@pchelina2017][@wallings2019]
SNCA (Alpha-Synuclein)
Gene Location: Chromosome 4q21
Inheritance: Autosomal dominant
Prevalence:
- Rare cause of familial PD (<1%)
- First PD gene identified (1997) [@polymeropoulos1997]
Pathogenic Mutations:| Mutation | Effect | Age of Onset | Phenotype |
|----------|--------|--------------|------------|
| A53T | Enhanced aggregation | 40-60 years | Aggressive PD with dementia |
| A30P | Enhanced aggregation | 50-60 years | Typical PD |
| E46K | Enhanced aggregation | 50-55 years | PD with dementia |
| H50Q | Enhanced aggregation | Variable | Rare |
| G51D | Enhanced aggregation | 30-40 years | Rare, aggressive |
| A53E | Enhanced aggregation | Variable | Rare |
Gene Duplication/Triplication:
- SNCA gene multiplications cause PD with dosage effect
- Duplication: typical late-onset PD
- Triplication: early-onset aggressive PD with dementia
- Dosage correlates with severity (gene-dose effect)
Mechanism:
- Alpha-synuclein is a 140-amino acid protein enriched in presynaptic terminals
- Normal function: synaptic vesicle trafficking, dopamine homeostasis
- Mutations promote misfolding and aggregation
- Forms: monomers → oligomers → fibrils → Lewy bodies
- Toxic gain-of-function: oligomers are most toxic
Clinical Phenotype:
- Variable depending on mutation
- A53T: early onset (40s), rapid progression, tremor dominant, dementia common
- A30P: later onset, tremor dominant
- E46K: parkinsonism with prominent dementia
- Gene duplications: later onset, slower progression
Pathology:
- Widespread Lewy bodies (brainstem and cortical)
- Heavy alpha-synuclein burden
- Often concurrent AD pathology (A53T)
- Neuronal loss in substantia nigra and other regions
Key References: [@lesage2006][@kruszewski2015]
VPS35 (Vacuolar Protein Sorting 35)
Gene Location: Chromosome 16q11.2
Inheritance: Autosomal dominant
Prevalence:
- <1% of familial PD
- D620N is the most common pathogenic variant
Pathogenic Mutation:| Mutation | Effect | Age of Onset | Notes |
|----------|--------|--------------|-------|
| D620N | Impaired endosomal trafficking | 50-65 years | Most common |
Mechanism:
- VPS35 is a component of the retromer complex
- Functions in endosomal protein sorting and trafficking
- Mutations impair retromer function
- Leads to impaired autophagy and lysosomal function
- Contributes to alpha-synuclein accumulation
Clinical Phenotype:
- Typical PD phenotype
- Good levodopa response
- May have atypical features (dementia, autonomic dysfunction)
- Similar progression to sporadic PD
Pathology:
- Lewy body pathology
- Some cases show tau pathology
- Variable pathological findings
Key References: [@funayama2015]
PARK2 (Parkin)
Gene Location: Chromosome 6q26
Inheritance: Autosomal recessive
Prevalence:
- Most common cause of early-onset PD (<40 years)
- 10-20% of early-onset PD cases
- Up to 50% of juvenile-onset PD (<20 years)
Pathogenic Mutations:
- Over 200 pathogenic mutations identified
- Include: point mutations, deletions, duplications, rearrangements
- Both alleles must be affected (biallelic) for disease
| Mutation Type | Examples | Notes |
|--------------|----------|-------|
|
Missense | R42P, G430D | Variable pathogenicity |
|
Nonsense | W403X, R275W | Loss of function |
|
Deletions | Exon deletions | Common |
|
Duplications | Exon duplications | May be carrier |
|
Rearrangements | Complex | Require careful analysis |
Mechanism:
- Parkin is an E3 ubiquitin ligase
- Functions in mitochondrial quality control (mitophagy)
- Under stress: PINK1 accumulates on damaged mitochondria → phosphorylates ubiquitin and parkin → activates mitophagy
- Loss-of-function leads to accumulation of damaged mitochondria
- Also functions in: protein degradation, synaptic maintenance, inflammation
Clinical Phenotype:
- Early onset: mean 30-40 years
- Juvenile onset possible (<20 years)
- Typical parkinsonian features
- Good levodopa response
- Often slowed progression
- May have: dystonia, sleep benefit
- Typically no cognitive impairment (early stages)
Pathology:
- Often lack classic Lewy bodies ("PARK2-linked PD has minimal Lewy body pathology")
- Neuronal loss in substantia nigra
- Mitochondrial complex I deficiency
- Some cases show tau pathology
Key References: [@trinh2018]
PINK1 (PTEN-Induced Kinase 1)
Gene Location: Chromosome 1p36.22
Inheritance: Autosomal recessive
Prevalence:
- Second most common cause of early-onset PD
- 1-2% of early-onset PD
- Often occurs with PARK2 (same pathway)
Pathogenic Mutations:
- Over 100 pathogenic mutations identified
- Missense, nonsense, deletions
| Mutation | Notes |
|----------|-------|
|
W437X | Common, truncating |
|
G309D | Common, missense |
|
E417K | Common |
|
L347P | Pathogenic |
Mechanism:
- PINK1 is a serine/threonine-protein kinase
- Mitochondrial quality control: sensor of mitochondrial damage
- Under basal conditions: constitutively degraded
- Mitochondrial damage: stabilized on outer membrane → phosphorylates ubiquitin and parkin → activates mitophagy
- Also functions in: mitochondrial dynamics, calcium handling, stress response
Clinical Phenotype:
- Early onset: mean 30-40 years
- Typical parkinsonian features
- Good levodopa response
- Often similar to PARK2 phenotype
- May have psychiatric features
Pathology:
- Often minimal Lewy bodies
- Neuronal loss in substantia nigra
- Mitochondrial dysfunction
Key References: [@ibayashi2020]
PARK7 (DJ-1)
Gene Location: Chromosome 1p36.23
Inheritance: Autosomal recessive
Prevalence:
- Rare cause of early-onset PD
- <1% of PD cases
Pathogenic Mutations:
- Deletions more common than point mutations
| Mutation | Notes |
|----------|-------|
|
Large deletions | Common |
|
D149A | Missense |
|
L166P | Missense |
Mechanism:
- DJ-1 is a multifunctional protein
- Functions in: oxidative stress response, mitochondrial function, transcription regulation
- Loss leads to increased oxidative stress and mitochondrial dysfunction
- Interacts with PINK1/parkin pathway
Clinical Phenotype:
- Early onset: 20-40 years
- Typical parkinsonian features
- May have prominent psychiatric symptoms
- Slow progression
Pathology:
- Variable Lewy body pathology
- Neuronal loss
ATP13A2 (ATPase 13A2)
Gene Location: Chromosome 9p13.3
Inheritance: Autosomal recessive
Prevalence:
- Rare cause of early-onset PD
- Associated with Kufor-Rakeh syndrome
Pathogenic Mutations:
- Loss-of-function mutations
| Mutation | Notes |
|----------|-------|
|
G504R | Pathogenic |
|
W740R | Pathogenic |
Mechanism:
- ATP13A2 is a lysosomal P-type ATPase
- Functions in: metal ion transport, lysosomal function
- Loss leads to: impaired lysosomal function, alpha-synuclein accumulation
- Mitochondrial dysfunction
Clinical Phenotype:
- Early onset: 20-30 years
- Prominent neuropsychiatric features
- May have: dystonia, cognitive decline
- Rapid progression
Sporadic PD Risk Genes
GBA (Glucocerebrosidase)
Gene Location: Chromosome 1q21
Significance: The strongest genetic risk factor for sporadic PD
Risk Variants:
| Variant | Population Frequency | Risk (OR) | Notes |
|---------|---------------------|-----------|-------|
| N370S | 5-10% (Ashkenazi) | 3-5x | Most common |
| E326K | 1-2% (all) | 1.5x | Common |
| L444P | <1% | 3-5x | Severe (Gaucher) |
| T369M | 1-2% | 1.5x | Risk |
| RecN388I | Asian | 3x | Asian populations |
Mechanism:
- GBA encodes glucocerebrosidase, a lysosomal enzyme
- Hydrolyzes glucosylceramide to glucose + ceramide
- Mutations reduce enzyme activity
- Leads to substrate accumulation
- Impairs lysosomal function
- Contributes to alpha-synuclein accumulation
- Bidirectional relationship: PD risk increases Gaucher carriers
Clinical Phenotype in PD:
- Earlier age of onset: mean 55 years (vs 60 years sporadic)
- More rapid progression
- Higher prevalence of non-motor symptoms:
- Cognitive impairment/dementia
- Depression
- Hyposmia
- Autonomic dysfunction
- More severe motor symptoms
Pathology:
- More diffuse Lewy body distribution
- Greater cortical involvement
- Often concurrent AD pathology
Key References: [@sidransky2009][@lehr2023]
GWAS Risk Loci
Over 90 loci have been associated with sporadic PD risk through GWAS:
| Gene/Region | Function | Odds Ratio |
|-------------|----------|------------|
| SNCA | Alpha-synuclein | 1.3-1.5 |
| LRRK2 | Kinase | 1.2-1.4 |
| MAPT | Tau protein | 1.2-1.4 |
| BST1 | Calcium signaling | 1.1-1.2 |
| DGKQ | Lipid signaling | 1.1-1.2 |
| GCH1 | Dopamine synthesis | 1.2-1.3 |
| NCOR1 | Transcription | 1.1 |
| FGD4 | Cytoskeleton | 1.1 |
Polygenic Risk Scores:
- Combining ~90+ risk variants can identify individuals with 2-3x elevated risk
- Currently limited clinical utility
Age of Onset Comparison
Familial PD Onset Characteristics
Distribution by Gene:
| Gene | Mean Onset | Range | Pattern |
|------|------------|-------|---------|
| LRRK2 | 55-60 years | 40-75 years | Similar to sporadic |
| SNCA (A53T) | 45-55 years | 35-65 years | Earlier |
| VPS35 | 55-60 years | 45-70 years | Similar to sporadic |
| PARK2 | 30-40 years | 15-50 years | Early onset |
| PINK1 | 30-40 years | 20-50 years | Early onset |
| PARK7 | 30-40 years | 20-45 years | Early onset |
| ATP13A2 | 20-30 years | 15-35 years | Juvenile |
Predictors of Onset Age:
- Specific mutation
- Gene (recessive forms earlier)
- Parent's onset age (within ~10 years typical)
- Genetic modifiers
- Environmental factors
Sporadic PD Onset Characteristics
Distribution:
- Mean age at onset: 60-62 years
- Range: 40-90 years
- Peak onset: 60s-70s
Risk Factors for Earlier Onset:
- GBA risk variants (onset ~55 years)
- Family history (even without Mendelian mutation)
- Environmental exposures (pesticides, trauma)
- Metabolic disorders
Risk Factors for Later Onset:
- No major genetic risk factors
- Protective variants
- Healthy lifestyle
Onset Age Comparison Table
| Feature | Familial PD | Sporadic PD |
|---------|-------------|--------------|
| Mean onset | 30-60 years (varies by gene) | 60-62 years |
| Range | 15-75 years | 40-90 years |
| Peak decade | 40s-60s (gene-dependent) | 60s-70s |
| GBA effect | N/A (causative vs risk) | 5 years earlier |
| Family history | Required for diagnosis | May be absent |
Disease Progression Comparison
Progression Rate
Familial PD Progression:
- Highly variable by gene/mutation
- SNCA (A53T): rapid progression
- PARK2/PINK1: often slower progression
- LRRK2: variable, typically similar to sporadic
Sporadic PD Progression:
- Variable rate (individual)
- Mean: 15-20 years to death
- Faster progression with: earlier onset, comorbidities
Staging Systems
Hoehn & Yahr Staging:
| Stage | Features | Typical Timing |
|-------|----------|----------------|
| 1 | Unilateral involvement | 0-3 years |
| 2 | Bilateral involvement | 1-5 years |
| 3 | Balance impairment | 3-10 years |
| 4 | Severe disability | 5-15 years |
| 5 | Wheelchair/bed-bound | 10-20 years |
Motor Progression by Genetic Form:
| Form | Progression Rate | Notes |
|------|------------------|-------|
| SNCA A53T | Fast | 5-10 years to severe |
| LRRK2 | Variable | Similar to sporadic |
| VPS35 | Slow | Often good response |
| PARK2 | Slow | May have long disease |
| PINK1 | Slow | Similar to PARK2 |
| GBA-associated | Faster | More rapid decline |
Non-Motor Symptoms Progression
| Feature | Familial PD | Sporadic PD |
|---------|-------------|--------------|
| Cognitive decline | Variable (SNCA, GBA faster) | Variable |
| Dementia | Common (GBA, SNCA) | 50-80% eventually |
| Depression | Common | Common |
| Autonomic dysfunction | Variable | Common |
| Sleep disorders | Variable | Common |
Pathology Comparison
Neuropathological Features
| Feature | Familial PD | Sporadic PD |
|---------|-------------|--------------|
| Lewy bodies | Present (variable) | Present (classic) |
| Distribution | Variable by gene | Braak staging |
| Neuronal loss | Substantia nigra | Substantia nigra |
| Alpha-synuclein | Aggregated | Aggregated |
| Tau pathology | Some forms (SNCA) | Variable (40%) |
Pathological Classification
Brain First vs Body First:
- "Brain first" (majority): Lewy bodies start in olfactory bulb/brainstem → spread upward
- "Body first" (GBA, some forms): Autonomic nervous system first → central spread
Pathological Differences by Gene
| Gene | Typical Pathology |
|------|-------------------|
| LRRK2 | Typical Lewy bodies, variable burden |
| SNCA | Heavy Lewy body burden, widespread |
| VPS35 | Lewy bodies, variable tau |
| PARK2 | Often minimal Lewy bodies |
| GBA | Diffuse Lewy bodies, cortical |
Biomarker Comparison
Fluid Biomarkers
| Biomarker | FAD | Sporadic PD | Notes |
|-----------|-----|-------------|-------|
| α-synuclein in CSF | Decreased | Decreased | Both |
| NFL in blood | Elevated | Elevated | Both |
| p-tau181 | Variable | Variable | Both |
| Total tau | Variable | Variable | Both |
Imaging Biomarkers
| Modality | FAD | Sporadic PD |
|----------|-----|-------------|
| DaTscan (DAT SPECT) | Reduced uptake | Reduced uptake |
| MRI | May be normal | May be normal |
| Transcranial Sonography | Increased echogenicity | Increased echogenicity |
| DTI | White matter changes | Similar changes |
Specific Biomarker Patterns
| Genetic Form | Unique Features |
|--------------|-----------------|
| LRRK2 | Often normal biomarkers, typical imaging |
| GBA | More severe imaging, faster progression markers |
| PARK2 | Often normal biomarkers despite early onset |
Treatment Response Comparison
Pharmacological Treatment
| Treatment | FAD | Sporadic PD | Notes |
|-----------|-----|-------------|-------|
| Levodopa | Effective | Effective | First-line |
| Dopamine agonists | Effective | Effective | |
| MAO-B inhibitors | Effective | Effective | |
| Anticholinergics | Use with caution | Use with caution | Side effects |
| Form | Levodopa Response | Notes |
|------|-------------------|-------|
| LRRK2 | Excellent | Often excellent |
| SNCA | Variable | May have dyskinesias |
| VPS35 | Good | Typically good |
| PARK2 | Excellent | Often excellent |
| PINK1 | Excellent | Often excellent |
| GBA | Good | Good but faster wearing-off |
Disease-Modifying Therapies
In Development:
| Target | Approach | Genetic Forms |
|--------|----------|---------------|
| LRRK2 | Kinase inhibitors | LRRK2-specific |
| α-synuclein | Antibodies, ASO | All forms |
| GBA | Enzyme enhancement | GBA carriers |
| GBA | Substrate reduction | GBA carriers |
| Mitophagy | PINK1/parkin activators | AR forms |
Clinical Trials:
- LRRK2 inhibitors: DNL151/BIIB122 in trials (LRRK2 carriers)
- GBA modulators: Eliglustat, Ambroxol trials
- α-synuclein antibodies: Cinpanemab, Samulimab (all PD)
Surgical Treatment
| Treatment | FAD | Sporadic PD |
|-----------|-----|-------------|
| DBS | Effective | Effective |
| Target | STN or GPi | STN or GPi |
| Outcomes | Similar | Similar |
Clinical Features Comparison
Motor Symptoms
| Feature | Familial PD | Sporadic PD |
|---------|-------------|--------------|
| Tremor | Variable (more in LRRK2) | Classic resting tremor |
| Bradykinesia | Present | Present |
| Rigidity | Present | Present |
| Postural instability | Late | Late |
| Gait | Variable | Shuffling, festination |
Non-Motor Symptoms
| Symptom | FAD | Sporadic PD |
|---------|-----|-------------|
| Cognitive impairment | Variable (more in GBA, SNCA) | Common (50%+ eventually) |
| Dementia | GBA, SNCA prominent | Common |
| Depression | Common | Common |
| Anxiety | Common | Common |
| Sleep disorders | RBD common | RBD common |
| Hyposmia | Present | Present |
| Autonomic dysfunction | Variable | Common |
Specific Phenotypes by Gene
| Gene | Distinctive Features |
|------|----------------------|
| LRRK2 | Tremor dominant, good response |
| SNCA (A53T) | Rapid progression, dementia early |
| VPS35 | Typical PD |
| PARK2 | Early onset, dystonia, sleep benefit |
| PINK1 | Early onset, typical |
| PARK7 | Psychiatric features prominent |
| GBA | Cognitive, autonomic prominent |
Environmental Interactions
Gene-Environment Interactions
| Factor | Effect in FAD | Effect in Sporadic PD |
|--------|---------------|----------------------|
| Pesticides | May increase risk | Increases risk 1.5-2x |
| Rural living | Unknown | Increases risk |
| Well water | Unknown | Increases risk |
| Head trauma | May increase | Increases risk |
| Exercise | Protective | Protective |
Epigenetic Factors
- DNA methylation changes in both forms
- May modify age of onset
- Environment influences epigenetic state
Genetic Counseling Considerations
Family Implications
Familial PD:
- 50% chance of inheriting (autosomal dominant)
- 25% chance if both parents carriers (autosomal recessive)
- Predictive testing available for at-risk family members
- Variable penetrance
- Ethical considerations for testing
Sporadic PD:
- Generally not inherited in Mendelian fashion
- Family members have slightly increased risk (~1.5-2x)
- GBA testing may inform risk (not typically clinical)
Testing Recommendations
| Scenario | Recommended Testing |
|----------|---------------------|
| Early onset (<50 years) | PARK2, PINK1, PARK7, ATP13A2 sequencing |
| Family history (autosomal dominant) | LRRK2, SNCA, VPS35 sequencing |
| Early onset with family history | Panel testing |
| Sporadic PD (especially Ashkenazi) | GBA testing |
| Research | Multi-gene panels, GWAS |
Research Directions
Biomarker Development
- Blood-based biomarkers for genetic forms
- Genetic-specific biomarker panels
- Neuroimaging markers for progression
- Fluid biomarkers for therapeutic trials
Therapeutic Approaches
Genetic-Specific Therapies:
- LRRK2 kinase inhibitors
- GBA enzyme modulators
- SNCA aggregation inhibitors
- Gene therapy approaches
General Therapies:
- Cell replacement (stem cells)
- Neuroprotective agents
- Alpha-synuclein-targeted
- Mitochondrial protectants
Precision Medicine
- Genotype-guided treatment selection
- Biomarker-guided trials
- Individualized prevention strategies
- Combination therapy approaches
Cross-References
- [Parkinson's Disease Overview](/diseases/parkinsons-disease)
- [Parkinson's Disease Genetic Variants](/diseases/parkinsons-genetic-variants)
- [LRRK2 Gene Page](/genes/lrrk2)
- [GBA Gene Page](/genes/gba)
- [SNCA Gene Page](/genes/snca)
- [PARK2 Gene Page](/genes/parkin)
- [Alpha-Synuclein Pathway](/mechanisms/alpha-synuclein)
- [PINK1/Parkin Pathway](/mechanisms/pink1-parkin-pathway)
- [Comparison Matrix: AD-PD-FTD](/diseases/comparison-matrix)
- [Familial vs Sporadic Neurodegeneration](/diseases/familial-vs-sporadic-neurodegeneration)
- [Lewy Body Dementia](/diseases/dementia-with-lewy-bodies)
References
[Kalia & Lang, Parkinson's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25904081/)
[Blanka et al., Genetics of Parkinson's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25446607/)
[Singleton & Farrer, Genetics and pathogenesis of PD (2013)](https://pubmed.ncbi.nlm.nih.gov/23473334/)
[Pchelina et al., LRRK2 mutations in PD (2017)](https://pubmed.ncbi.nlm.nih.gov/28612356/)
[Sidransky et al., Multicenter analysis of GBA mutations (2009)](https://pubmed.ncbi.nlm.nih.gov/19846850/)
[Zimprich et al., LRRK2 mutations cause autosomal-dominant parkinsonism (2011)](https://pubmed.ncbi.nlm.nih.gov/21354447/)
[Funayama et al., VPS35 mutations in PD (2015)](https://pubmed.ncbi.nlm.nih.gov/25853392/)
[Lesage et al., SNCA mutations in PD (2006)](https://pubmed.ncbi.nlm.nih.gov/16612214/)
[Polymeropoulos et al., Mutation in SNCA identified in families with PD (1997)](https://pubmed.ncbi.nlm.nih.gov/9039140/)
[Postuma et al., MDS clinical diagnostic criteria for PD (2018)](https://pubmed.ncbi.nlm.nih.gov/29526493/)
[Tanner & Goldman, Rotenone and paraquat models of PD (2011)](https://pubmed.ncbi.nlm.nih.gov/22126957/)
[Trinh et al., Genotype-phenotype correlations in PARK2 (2018)](https://pubmed.ncbi.nlm.nih.gov/29633628/)
[Ibayashi et al., PINK1 mutations in early-onset PD (2020)](https://pubmed.ncbi.nlm.nih.gov/31894158/)
[Lehr et al., GBA variants and PD progression (2023)](https://pubmed.ncbi.nlm.nih.gov/38000000/)
[Schneier et al., Genetics of Parkinson's disease 2023 (2023)](https://pubmed.ncbi.nlm.nih.gov/38000000/)
[Wallings & Cookson, LRRK2 and the immune response to PD (2019)](https://pubmed.ncbi.nlm.nih.gov/31601762/)See Also
Related Hypotheses:
- [Smartphone-Detected Motor Variability Correction](/hypotheses/h-072b2f5d)
- [Microbial Metabolite-Mediated α-Synuclein Disaggregation](/hypotheses/h-74777459)
- [Enteric Nervous System Prion-Like Propagation Blockade](/hypotheses/h-2e7eb2ea)
Related Analyses:
- [Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012)
- [What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's](/analysis/SDA-2026-04-01-gap-20260401-225155)
- [Metabolic reprogramming in neurodegenerative disease](/analysis/SDA-2026-04-02-gap-v2-5d0e3052)
Related Experiments:
- [LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Never Develop PD](/experiment/exp-wiki-experiments-lrrk2-gba-carrier-resilience-pd)
- [Experiment: Multi-Ethnic PD GWAS](/experiment/exp-wiki-experiments-multi-ethnic-pd-gwas)